While the primary mechanism of action in CPVT has been a subject of debate, recent studies suggest that its efficacy may stem from RyR2 blockade, potentially inhibiting ryanodine-receptor (RyR2)-mediated sarcoplasmic reticulum calcium release [89,90]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.